BAGS OF KINDNESS
“Giving Back to the Community”, a theme
that is part of Park’NFly’s CSR strategy,
saw caring employees support the Ronald
McDonaldHouse Charities. Teammembers
fromacross Canada visitedHouses in
Vancouver, Edmonton, Winnipeg, Toronto,
Ottawa andMontreal to help support over
650 families by assembling snack bags
filled with goods and non-perishable food
items. The snack bags were a welcome and
healthy treat for families attending to their
seriously sick kids in hospitals.
SPHERE
#42
2017
07
SHADOWY, GREENY ENGINEERS AT
HK ELECTRIC
The top three “Happy Green Community
Ambassadors” selected under HKElectric’s
Smart Power Campaign shadowed the
company’s environmental engineers and
worked at its headquarters and Lamma
Power Station early this year.
Infrastructure
POWER FIRST – LAUNCH OF
EMERGENCY PACK
UK Power Networks launched a new
emergency pack that will help consumers
on its Priority Services Register in case
of a power cut. Although outages are rare,
they still happen occasionally, and can
be worrying for vulnerable people. The
new pack contains helpful items such as a
plug-in-the-wall torch that automatically
switches on when there is a power cut, a
glow stick, and a storage bottle where
people can keep vital information in case
of an emergency.
BEST PLACE TOWORK –
THREE YEARS RUNNING!
UKPower Networks was one of the top 30
best companies to work for in the country,
for the third straight year. The rankings,
based on a detailed employee survey, show
UKPower Networks’ ability and capacity to
put their employees first and
to involve employees in
the community. The
power company
has also won the
“Utility of the
Year” title for
the second
year in a row,
and the third
time since
2012, which is
unprecedented
in the industry.
OTHERS
Chi-Med first Phase III trial success
Hutchison China MediTech (Chi-Med) announced positive results for a Phase III
clinical trial of Fruquintinib in colorectal cancer patients. This marks a huge
development for Chi-Med after 15 years of investment and research. It is the
first ever home-grown, Chinese-discovered and developed drug in a mainstream
therapeutic area (i.e. a major cancer) to get through Phase III trials in China.
Colorectal cancer is the second most common cancer in China, with about
380,000 new cases per year.
